Amgen rolls out restructure with 274 R&D redundancies in Seattle

Almost 300 workers will be made redundant at an R&D plant in Seattle, Washington as Amgen rolls out its restructure plan.

According to a Worker Adjustment and Retraining Notification (WARN) published by the Washington State Employment Security Department this week, 274 workers will be laid off at the firm’s administration and R&D facility which, along with a manufacturing site in Bothell, has been earmarked for closure.

The job loss forms part of a restructure plan announced by the firm in July which warned 15% of its total workforce, equating to nearly 3,000 jobs, would be axed in order to save $700m (€540m) a year.

At the time CEO Bob Bradway told investors during a conference call to discuss Q2 results that Amgen plans to “close all [its] facilities in Washington and Colorado before the end of 2015,” with the process of exiting these sites beginning in the third quarter.

The California-headquartered reports its Q3 2014 financial results next week.